Molecular mechanisms of insulin secretion;Mécanismes moléculaires de l'insulinosécrétion

Diabetes and Metabolism

Volumn 28, Issue 6 SUPPL., 2002, Pages

  Bataille, D ^a  

^a INSERM   (France)

Author keywords

Gliclazide; Glucoses metabolism; Insulin secretion; Sulfonylureas; Type 2 diabetes mellitus

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CALCIUM CHANNEL; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; POTASSIUM;

BINDING SITE; CONFERENCE PAPER; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; MEMBRANE DEPOLARIZATION; ANIMAL; BIOLOGICAL MODEL; CALCIUM SIGNALING; DRUG EFFECT; EXOCYTOSIS; NOTE; PANCREAS ISLET; PHYSIOLOGY; SECRETION;

ANIMALS; CALCIUM SIGNALING; EXOCYTOSIS; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; POTASSIUM; POTASSIUM CHANNELS; SULFONYLUREA COMPOUNDS;

EID: 0036997675     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Cook DL, Taborsky GJ. β-cell function and insulin secretion. In: Ellenberg's & Rifkin's Diabetes Mellitus: Theory and Practice, Porte D & Sherwin R (eds), Appleton & Lange, Stamford, 1996, 49-73.
2. Fajan SS. Classification and diagnosis of diabetes mellitus. In: Ellenberg's & Rifkin's Diabetes Mellitus: Theory and Practice, Porte D & Sherwin R (eds), Appleton & Lange, Stamford, 1996, 357-372.
3. Van Haeften TW, Pimenta W, Mitrakou A, et al. Disturbances in β-cell function in impaired fasting glycemia. Diabetes, 2002, 51, S665-S670.
4. Alarcon C, Lincoln B, Rhodes CJ. The biosynthesis of the subtilisin-related proprotein convertase PC3, but not that of the PC2 convertase, is regulated by glucose in parallel to proinsulin biosynthesis in rat pancreatic islets. J Biol Chem, 1993, 268, 4276-4280.
5. Ashcroft FM, Harrison DE, Ashcroft SJH. Glucose induces closure of single potassium channels in isolated rat pancreatic β-cells. Nature, 1984, 312, 446-448.
6. Ashcroft SJH, Ashcroft FM. Properties and functions of ATP-sensitive potassium channels. Cell Signal, 1990, 2, 197-214.
7. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science, 1995, 268, 423-426.
8. Gros L, Bataille D. Canaux potassiques ATP-dépendants et mode d'action des sulfonylurées. Med Therap Endocrinol, 2000, 2 (Hors série no 2), 3-12.
9. Kelly RP, Sutton R, Ashcroft FM. Voltage-activated calcium and potassium currents in human pancreatic β-cells. J Physiol, 1991, 443, 175-192.
10. Ämmälä C, Eliasson L, Bokvist K, et al. Exocytosis elicited by action potentials and voltage-clamp calcium currents in individual mouse pancreatic β-cells. J Physiol, 1993, 472, 665-688.
11. 2+ pathway. J Biol Chem, 1999, 274, 10869-10876.
12. Virsolvy-Vergine A, Leray H, Kuroki S, et al. Endosulfine, an endogenous peptidic ligand for the sulfonylurea receptor: Purification and partial characterization from ovine brain. Proc Natl Acad Sci USA, 1992, 89, 6629-6633.
13. ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia, 2001, 44, 1019-1025.
14. Schwarz ER, Reffelmann T, Kloner RA. Clinical effects of ischemic preconditioning. Curr Opin Cardiol, 1999, 14, 340-348.
15. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol, 1999, 33, 119-124.
16. Legtenberg RJ, Houston RJ, Oeseburg B, Smits P. Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart. Eur J Pharmacol, 2001, 419, 85-92.
17. Ovunc K. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol, 2000, 23, 535-539.
18. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes, 2002, 51, 808-812.
19. Goncalves JV, Caldeira J. Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas. Rev Port Cardiol, 2001, 20, 439-445.
20. Weih M, Amberger N, Wegener S, et al. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke, 2001, 32, 2029-2032.
21. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation, 2001, 103, 3111-3116.
22. Reimann F, Ashcroft FM, Gribble FM. Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes, 2001, 50, 2253-2259.